Skip to main content

Table 1 Demographics and tumor information for primary and second tumors stratified by progesterone receptor (PR) status

From: ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors

Group Primary tumor Second tumor
(1) PR+ to PR+ (n = 10)
 Age (±SD), range 53.8 (±16.9), 37–84 61.4 (±16.7), 40–90
 Tumor type DCIS 1; IDC 8; ILC 1 DCIS 1; IDC 7; ILC 2
 Hormonal therapy Yes = 10 (6 tamoxifen, 4 type unknown)
(2) PR+ to PR− (n = 6)
 Age (±SD), range 54 (±7.8), 42–62 63.3 (±7.1), 55–74
 Tumor type DCIS 1; IDC 3; ILC 1; IDC and ILC 1 DCIS 2; IDC 3; ILC 1
 Hormonal therapy Yes = 6 (4 tamoxifen, 2 aromatase inhibitor)
(3) PR− to PR− (n = 8)
 Age (±SD), range 60.1 (±10.6), 46–79 63.3 (±11.1), 48–80
 Tumor type DCIS 1; IDC 7 DCIS 1; IDC 7
 Hormonal therapy No = 5; Yes = 3 (all tamoxifen)
  1. DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma